Oncology-focused digital well being firm Flatiron Well being introduced it entered right into a strategic partnership with Huge Bio, an organization that helps most cancers sufferers discover and enroll in scientific trials.
Flatiron Well being is an oncology-focused well being know-how firm that provides a platform aimed toward optimizing the scientific trial course of, together with choosing trial websites and figuring out sufferers who’re eligible for trials. The corporate additionally supplies digital well being file companies and scientific resolution assist instruments to suppliers.
Huge Bio makes use of AI to establish most cancers sufferers eligible for scientific trials and join them and their docs to relevant trials.
Flatiron will use Huge Bio’s database on a per-study foundation to seek out sufferers who aren’t enrolled in scientific trials however stay near a trial web site.
These sufferers will then be directed to one among Flatiron’s analysis websites, the place they are often introduced on as new sufferers and presumably enrolled in a scientific trial using Flatiron’s proprietary know-how and consolidated affected person identification companies.
“Flatiron Well being is happy to affix forces with Huge Bio, combining experience and assets to advance customized remedy choices for most cancers sufferers,” Michael Bierl, vp of scientific analysis partnerships and normal supervisor Europe at Flatiron Well being, mentioned in a press release.
“By leveraging Huge Bio’s sturdy community and database, we are able to proceed to make the most of our cutting-edge instruments to empower websites to progress analysis, improve workflows and efficiencies, speed up scientific hint tempo whereas making certain numerous affected person populations have entry to life-changing remedies which may in any other case be out of attain.”
Arturo Loaiza-Bonilla, cofounder and chief medical officer at Huge Bio, mentioned the corporate’s mission is to make entry to scientific trials patient-centric and assure the correct affected person is matched to the correct trial on the proper time, no matter the place they stay.
“By pairing our AI-driven platform and concierge companies with Flatiron Well being’s intensive analysis infrastructure, we may also help physicians and care groups expedite trial enrollment, cut back disparities in entry and enhance outcomes for extra sufferers,” Loaiza-Bonilla mentioned in a press release.
THE LARGER TREND
In March, the College of Colorado Most cancers Heart (CU Most cancers Heart) and Flatiron Well being joined forces to make scientific trials extra productive by decreasing the executive burden for researchers.
The partnership introduced Flatiron Medical Pipe to the CU Most cancers Heart and UCHealth, which allowed scientific trial information to maneuver straight from digital well being information to digital information seize methods. The know-how additionally transfers data straight from the EHR to trial databases.
Flatiron Medical Pipe is an digital well being file to digital information seize connector that captures and transfers trial information.
That very same month, Flatiron collaborated with NRG Oncology, a scientific analysis consortium within the Nationwide Most cancers Institute’s Nationwide Medical Trials Community, to make use of Flatiron Medical Pipe in a multicenter NRG scientific trial.
In February, Flatiron partnered with Precise Sciences to extend scientific proof technology for Precise Sciences’ molecular residual illness check Oncodetect. The alliance makes use of Flatiron’s scientific analysis platform to guage a variety of stable tumor sorts.
The intention was to collect scientific proof in a real-world setting and disparate affected person populations by utilizing group care settings which are usually underrepresented in scientific trials.
In January, DeepScribe partnered with Flatiron to deliver DeepScribe’s AI documentation to clinicians who use Flatiron’s OncoEMR, a cloud-based digital medical file platform.
The alliance made DeepScribe the primary ambient AI resolution companion for Flatiron Well being.
Final yr, Flatiron collaborated with the Affiliation of Most cancers Care Facilities (ACCC) to advertise entry to scientific trials in a group setting, enhance scientific research effectivity and enhance the gathering of study-related information.
In 2022, Huge Bio secured $9 million in financing. Revo Capital and Kenan Turnacioğlu led the spherical, with participation from DEG. The corporate used the funds to develop its operations globally, market itself and launch new merchandise.
Source link
